We prospectively randomized 47 patients with acute ischemic stroke of the middle cerebral artery of <24 hours' duration to either adjusted hypervolemic hemodilution or control treatment and followed them up for 90 days. Rapid hemodilution to a target hematocrit of 30-35% as monitored with bedside determinations was achieved by using infusions of dextran 40, venesections, and infusions of additional crystalloid solution when necessary. There was no difference in the death rate between the two treatment groups. Of these 47 patients, 37 (19 in the hemodilution group and 18 in the control group) could be followed up for the entire study period of 3 months. The relative improvement in neurologic function from day 1 to days 8, 21, and 90 was significantly better in the hemodilution group than in the control group. In accordance, special tests for fine motor control of the paretic arm disclosed better performance in the hemodilution group. The frequency of patients with severe disability was significantly lower in the hemodilution group on days 8 and 21. Plasma viscosity (measured in 11 patients) was not affected by infusions of dextran 40. Vigorous hypervolemic hemodilution in patients with acute ischemic stroke is well tolerated and improves early neurologic outcome with an effect lasting at least 3 months. (Stroke 1990;21:1429-1434)
V ery few stroke patients arrive at the hospital within the first hours after onset. Irreversible damage to nonperfused brain regions is thus established in most patients on admission, and measures to induce reperfusion (e.g., thrombolytic therapy) come too late. Other therapeutic approaches seek to limit cerebral infarction by slowing cerebral metabolism, 1 controlling perifocal brain edema, 2 or enhancing collateral blood flow to the peri-infarct region. This is attempted by treatment with vasodilatation, 3 drugs that influence erythrocyte deformability, 4 or hemodilution. Hematocrit is the main determinant of whole-blood viscosity. Hematocrit is positively correlated with the size of cerebral infarcts, 5 and lowering hematocrit augments cerebral blood flow 6 and enhances oxygen delivery to the brain. 7 There is still no agreement about the optimal hematocrit, but experimental data suggest that a hematocrit of 30-35% best combines good rheological and oxygen-carrying properties of the blood. 8 Since many patients presenting with stroke are dehydrated and hypovolemic, cerebral blood flow may be increased by volume expansion alone. 9 Because con-trolled clinical trials using normovolemic or only slightly hypervolemic hemodilution have reported conflicting results, 10 - 12 we conducted a prospective, randomized study to test the efficacy of adjusted hypervolemic hemodilution (HH) to reduce the neurologic deficit and disability in patients with acute ischemic stroke.
Subjects and Methods
All patients admitted between September 1984 and October 1986 to the medical or neurological clinic of the University Hospital of Zurich with the presumptive diagnosis of acute ischemic stroke of the middle cerebral artery were considered for inclusion in the study. We excluded patients with transient ischemic attack (normalization of neurologic deficit within 24 hours), cerebral hemorrhage or tumor as shown by computed tomography, brain stem infarction, impaired level of consciousness at the time of admission, a delay of >24 hours from the first symptom to onset of therapy, or hypoglycemia or other metabolic disturbances possibly linked to neurologic deficits. To avoid side effects of HH we also excluded patients with overt heart failure or angina pectoris at rest, acute or subacute myocardial infarction, a serum creatinine level of >300 /xmol/1, thrombocytopenia of <50,000/mm admission. Therefore, only 18.2% of the patients considered were included. The protocol was approved by the ethical committee of the medical clinic. Informed consent was required from the patient or his relatives. The included patients were randomized to either a group treated with HH or a control (C) group.
Patients were treated on regular wards. A peripheral venous catheter was inserted for infusion therapy, and the patients were monitored clinically several times a day for signs of volume overload. The infusion bottles used (dextran 40 or 0.9% saline) were blinded, and the raters assessing neurologic function were not aware of the patient's treatment group.
Patients randomized to the HH group first received a bolus injection of 20 ml i.v. dextran 1 (average molecular weight 1,000 Da). Then 500 ml dextran 40 (average molecular weight 40,000 Da; 10% solution in 0.9% saline) was infused over 1 hour. Phlebotomy was started during the last 15 minutes of the infusion and was completed after 500 ml blood had been drawn. After the first 500 ml of dextran 40, the patients received 1,000 ml of dextran 40 a day for 3 days. In patients with cardiac or renal failure, this maintenance dosage was reduced by 50%. Hematocrit was monitored every 2-6 hours at the bedside using a portable centrifuge (Compur Microspin M1100, Bayer-Schweiz AG, Zurich). The protocol required that hematocrit be reduced as rapidly as possible to 30-35%. To achieve this low hematocrit, in addition to the fixed dextran infusion protocol, further phlebotomies and infusion of electrolyte solution were often performed. The total amount of dextran infused was 3,500 ml in 14 and 2,000 ml (reduced dose) in eight of the 22 patients who completed the 3 days of HH therapy; a mean±SD of 770 ±460 ml blood was withdrawn by venesection, and a mean±SD of 2,000± 1,700 ml electrolyte solution was infused. Patients randomized to the C group received 500 ml of 0.9% saline a day for 3 days. All patients received 250 mg/day acetylsalicylic acid from day 5 on throughout the study period. In addition to bedside monitoring of (capillary) hematocrit, additional measurements were performed on days 5 and 21. In 20 patients (11 in the HH and nine in the C group) plasma viscosity was determined before (on admission at day 1) and during (at day 3) infusion therapy at shear rates of 1.18, 10.15, and 87.0 sec"
Neurologic function was assessed using a modified Mathew score 2 that measured level of consciousness and orientation (maximum score 14 points for normal function), visual and somatosensory functions (maximum score 6 points for normal function), tendon reflexes and muscle strength (motor function) (maximum score 29 points for normal function), and degree of disability (maximum score 28 points for normal function). A maximum total score of 77 points indicated normal neurologic function. Neurologic function was assessed on days 1, 2, 4, 8, 21, and 90. Speech was assessed separately using an aphasia short test on days 1, 21, and 90 as well as the Aachen asphasia test 13 on days 21 and 90. Special tests for assessing motor control were designed by one of us. In the light test the patient sits in front of a 50x70 cm rectangular board into which 10 light switches are imbedded in a random arrangement. A switch lights up. As soon as the patient depresses that switch another lights up in randomized order. The number of consecutively illuminated switches depressed within 30 seconds by the patient is counted. In the stick test the patient faces a 15 x 10 cm wooden board with rows of small holes designed to hold match-like wooden sticks. The number of sticks correctly inserted into the holes within 30 seconds is counted. The two tests have been validated in 32 normal volunteers aged 46-80 years. The volunteers scored a mean±SD of 20.1 ±3.1 points on the light test and a mean±SD of 18.2±2.2 points on the stick test. The light test was performed on days 2, 21, and 90, the stick test on days 21 and 90.
We compared the groups using the MannWhitney U test. We used Wilcoxon's matched-pairs signed-ranks test to compare changes in variables over time and performed the \ 2 test if indicated. To eliminate baseline differences in neurologic function, the relative change in scores was defined as a linear transformation and calculated as described by Gelmers et al 14 ;p<0.05 was considered to indicate a significant difference with a two-tailed test.
Results
We included 50 patients. Within the first day, three patients were withdrawn from the study (because of misdiagnosis [cerebral abscess] in one and because the doctor in charge of the patient changed treatment [thrombolysis, anticoagulation] in two). Of the remaining 47 patients, 25 were randomized to the HH and 22 to the C group. The two groups were well matched except for diastolic blood pressure, which was significantly higher in the C group (Table 1) . Ten patients could not be followed up for the entire study period. Eight (five in the HH and three in the C group) died, six early (on day 2 or 3) (five of giant cerebral infarcts and the other of acute myocardial infarction) and the other two late. One patient in the HH group refused to participate in the last follow-up examination. One patient in the C group with severe disability who lived in a nursing home missed the last Values are mean±SD mPaxsec at shear rate of 87.0 sec examination. Therefore, 37 patients (19 in the HH and 18 in the C group) were followed up for the entire study period and were evaluated for neurologic outcome. Their baseline characteristics were almost identical to those of the 47 patients shown in Table 1 . There is controversy about whether deceased patients should also be included in the evaluation. The Mathew score of 0 given for the dead is far removed from the score of any living subject, and such a score distorts disproportionally the distribution of values and therefore the statistical analysis. The main cause of death was giant cerebral infarcts. A severe neurologic deficit with a Mathew score of <40 points on admission was found in six of the eight patients who died compared with nine of the 39 patients who survived (p<0.05). As mortality did not differ significantly between the groups, only patients with complete follow-up were considered in the evaluation of neurologic outcome.
A reduction of the hematocrit to <35% was achieved in 21 (84.0%) of the 25 HH patients. Hematocrit (%) decreased by an average of 14.3 (30.6% of baseline hematocrit). The target hematocrit was reached an average of 8.8 hours after the start of HH treatment. Mean time from stroke onset to target hematocrit was 19.4 hours. Figure 1 illustrates the rapid and profound reduction of hematocrit in the HH group compared with hematocrit in the C group. Despite the fact that HH treatment was performed over only 3 days, hematocrit in the HH 
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group remained low for 3 weeks. Side effects such as anaphylactic reactions or renal failure did not occur. Hypervolemia may have contributed to the death of an 81-year-old diabetic man who died of a myocardial infarction on day 2. No other cardiovascular complications were observed. Because it changes with hematocrit, we did not measure whole-blood viscosity. On the other hand, we could not detect differences in plasma viscosity between the groups (Table 2) .
Total Mathew scores of the 37 patients with complete follow-up are given in Table 3 . The HH group had significantly higher total score on days 8, 21, and 90. By eliminating the baseline differences between groups, the relative change in neurologic function can be calculated (Figure 2 ). The HH group showed significantly better improvement for days 8 (/>=0.034), 21 (p=0.010), and 90 (p=0.050). Figure  2D includes relative change for the eight dead patients. The results are qualitatively the same, but because of huge standard deviations the difference between groups is no longer significant (p=0.346).
As for individual parts of the modified Mathew score, only the disability score showed significantly better results for the HH group on days 8 and 21 (Table 3) ; on day 90 there was only a trend in favor of the HH group (/J=0.077). Figure 3 shows the percentage of patients with severe disability; the HH group suffered significantly less frequent severe disability on days 8 and 21. The other neurologic functions comprising the modified Mathew score reveal only trends in favor of the HH group (Table  3) . Results of the aphasia short test and the Aachen aphasia test (not shown) did not disclose differences between the groups at any time.
The light and stick tests were performed separately for the upper right and left limbs so that results for the paretic side could be compared between groups (Table 4) . Although the light test scores at day 2 differed slightly but not significantly, outcome for the two groups at days 8 and 90 differed significantly and is strikingly in favor of the HH group. In contrast to this finding, the test for motor function in the modified Mathew score did not show any differences between groups at all. (Figure 2) . The clinical significance of this benefit is illustrated by the higher percentage of HH patients with only small residual disability compared with the C patients ( Figure 3) as well as by the results of tests of fine motor control (light and stick tests), which show better performance of the paretic arm and hand in the HH group (Table 4) . We think that the light test (which examines motor function, mainly of the arm) and the stick test (which covers skills and motor precision of hand and fingers) are clinically more relevant in describing motor impairment and its contribution to disability than the Mathew score (which measures only motor strength). Our findings stand against those of two recent trials with many patients 1516 that yielded negative results. Both large studies used normovolemic or only slightly hypervolemic hemodilution. The Scandinavian trial 15 followed a standard protocol of dextran infusion and venesection, achieving a modest reduction in hematocrit, to 37%, within 3-5 days. In many patients of the Italian trial, 16 hemodilution was insufficient, as demonstrated by mean hematocrits of 37.9% and 37.2% after 1 and 2 days of treatment, respectively. In a study performed by the Hemodilution in Stroke Study Group, 17 patients were treated on an intensive care unit and hemodilution was monitored with a Swan-Ganz catheter. Despite this sophisticated approach, satisfactory hemodilution was not obtained in most patients; hematocrit could be lowered to >15% of baseline values in only a third, and hematocrit declined by only 6% on the first day of treatment.
In our study, bedside monitoring of hematocrit and subsequent adjustments of infusion volume and venesections resulted in a hematocrit of <35% in 21 (84.0%) of 25 patients. Target hematocrit was attained an average of 19.4 hours after stroke onset and 8.8 hours after the start of HH therapy. Hematocrit values decreased by an average of 14.3% between days 1 and 2, corresponding to a reduction of 30.6% from the baseline value. Our results also demonstrate that adequate HH can be performed safely on a regular ward with careful clinical observation. Different intensities and speeds of hemodilution might explain the differences in clinical outcome of the trials noted here. Because many stroke patients present with hypovolemia, prompt and vigorous HH seems crucial in a situation where blood flow in the penumbra of an infarct must be improved. 18 On the other hand, it is clear that even optimal HH will not provide dramatic benefits but only modest effects on neurologic outcome, and these might get lost statistically in large trials with heterogeneous study populations.
We expected an early beneficial effect of HH and therefore closely monitored neurologic function in our patients during the first few days after stroke. However, it was only from day 8 on that the Mathew scores of the groups differed, with significantly higher scores for the HH group. The mechanism of action of HH in acute ischemic stroke in general and the reason for this delayed rather than immediate effect on recovery in particular is not known and therefore is open to speculation. Reversibly damaged cells may be functionally blocked and may recover only gradually.
In conclusion, adjusted HH exerts a positive effect on the neurologic recovery of patients with ischemic stroke. Evaluating the relative change in neurologic function takes into account the few patients in our study. Because of our strict evaluation criteria, the rapid effectiveness of hemodilution, and the consistency of clinical examination at one center, we think that our study, despite its small patient groups, represents a valid contribution to the discussion of the treatment of acute ischemic stroke. More patients should be treated in a randomized study with our protocol to confirm these encouraging results.
